So yesterday I had a fibroscan. Was not prepared for the physicality of the procedure. Felt like tiny fists hammering on my ribs. Not painful but not exactly comfortable. I was just told "it's like an ultrasound". Uh huh, sure. 😜

#radiology #fibroscan #liver

Redirecting

We describe #HBV infection in #Uganda, to determine #treatment eligibility. #Liver assessment by #fibroscan important to determine who should be treated.
Some drug resistance motifs seen in the context of #HIV.
@who.int @crick.ac.uk @ndm.ox.ac.uk #LSHTM #UVRI #MedSky
🇺🇬 🧪
doi.org/10.1016/j.ji...

Echosens Secures Its Spot as a Top Place to Work in 2025 by The Boston Globe Echosens has been recognized by The Boston Globe as one of Massachusetts' Top Places to Work in 2025 for its commitment to employee growth and culture.

Echosens Secures Its Spot as a Top Place to Work in 2025 by The Boston Globe #United_States #Echosens #FibroScan #Westborough #Top_Places_to_Work

Error - Cookies Turned Off

In 1203 🇮🇹 outpatients with #T2DM, #MASLD was present in 71% and significant fibrosis in 21%.

The EASL-EASD-EASO two-tier algorithm (#FIB4 → #FibroScan) showed high NPV but modest sensitivity, especially in patients with ↑BMI or ↑ALT ⚠️

🔗 dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/...

Weight gain >5% in MASLD? Liver risk almost doubles!

This study considered a global cohort of >10,000 MASLD patients 🌍

Reversing obesity brings risk back close to non-obese levels: dynamic weight matters ✅️

#MASLD #Obesity #MetabolicHealth #Fibroscan

journals.lww.com/hep/abstract...

FDA Accepts Echosens’ Intent Letter for Innovative Liver Disease Diagnostics Using FibroScan in Clinical Trials Echosens' FibroScan has received FDA approval to be used as a non-invasive endpoint in clinical trials for metabolic dysfunction-associated steatohepatitis.

FDA Accepts Echosens’ Intent Letter for Innovative Liver Disease Diagnostics Using FibroScan in Clinical Trials #USA #FDA_Approval #Echosens #FibroScan #Westborough

FDA Acceptance Marks a Milestone for FibroScan® in Non-Invasive Liver Diagnostics Echosens celebrates FDA's acceptance of FibroScan® as a surrogate endpoint for MASH clinical trials, potentially transforming liver disease evaluation.

FDA Acceptance Marks a Milestone for FibroScan® in Non-Invasive Liver Diagnostics #USA #FDA_Approval #Echosens #FibroScan #Westborough

FDA Paves the Way for Non-Invasive Liver Diagnosis with FibroScan® in MASH Trials The FDA has recognized Echosens' FibroScan® as a probable surrogate endpoint for MASH clinical trials, transforming liver disease diagnosis and treatment.

FDA Paves the Way for Non-Invasive Liver Diagnosis with FibroScan® in MASH Trials #MASH #Echosens #FibroScan #Westborough

Fibroscan, il nuovo gioiello della diagnostica è stato donato alle Malattie Infettive del San Donato Il dispositivo permette di definire la fase di sviluppo delle malattie croniche del fegato monitorandole e riducendo l’utilizzo della biopsia epatica solo in casi selezionati

➡️ Leggi l'articolo: #Fibroscan

Echosens Joins Forces with United Digestive to Enhance Non-Invasive Liver Diagnostics Access Across Southeast USA Echosens partners with United Digestive to enhance access to non-invasive liver diagnostics in Georgia and Florida, improving early disease detection and tailored care.

Echosens Joins Forces with United Digestive to Enhance Non-Invasive Liver Diagnostics Access Across Southeast USA #United_States #Echosens #FibroScan #United_Digestive #Georgia_and_Florida

ELASTOGRAPHY AND CAP ASSESSMENT FOR LIVER DISEASE: Training events and feedback representing clinical research programmes in South Africa, Uganda and Kenya Here we describe the FibroScan training events conducted at the Africa Health Research Institute (AHRI) in Somkhele, South Africa, at the KEMRI-Wellcome Trust Research Programme (KWTRP) in Kilifi, Ken...

This project in #Uganda #Kenya & #SouthAfrica also highlights #liverhealth evaluation with #ultrasound. Big #equity concerns as such tools are key to clinical care but not available in many settings.
#fibroscan #echosens #hepatitis #HBV #KWTRP #UVRI @ahri-news.bsky.social
doi.org/10.6084/m9.f...

Poster showing a report of training events and feedback for elastography and CAP assessment in South Africa, Uganda and Kenya.

Poster describing our training and use of #Fibroscan to collect #elastography and other data on liver health, including #MASLD and #HBV, by Motswedi Anderson @ahri-news.bsky.social, working through partnerships in Uganda #UVRI, and Kenya #KWTRP with @lou-downs.bsky.social
4/n

Echosens Earns 2024 Top Place to Work Honor from The Boston Globe Recognized as a top workplace in Massachusetts, Echosens showcases vibrant culture and commitment to employee well-being impacting liver health.

Echosens Earns 2024 Top Place to Work Honor from The Boston Globe #United_States #Boston_Globe #Echosens #FibroScan #Westborough

In the world of liver health, timely and precise diagnosis is the difference between effective management and severe complications. #Fibroscan #LiverSheawaveElastography
#FibroScan
#LiverFibrosis
#FibroScanTest
#LiverHealth
#HealthyLiver
#LiverDisease
phoenix-ultrasound.co.uk/blog/applica...

@EASLnews @EASLedu @QAnstee #fibroscan in NASH has a high NPV but much lower positive predictive value. If you see patients with high fibroscan that you biopsy and they turn out to have little or no fibrosis you know this already #ILC2019

@EASLedu you can dl myfibroscan app by @Echosens and calculate prob. active #NAFLD (PAN) score based on #fibroscan & CAP scores #ilc2017

@EASLedu Prof Ratziu: practically useful but still "mysterious" algorithm to predict #NASH based on CAP and #fibroscan score. #ILC2017

@EASLedu Prof. Dufour highlights data showing CAP >220 dB/m can help predict decompensation in high #fibroscan score pts #ilc2017

@AASLDtweets Dr. Donato: #fibroscan predicts fibrosis stages well in #HCV DAA treated pts before & after transplant #livermtg16

Excited about new "gizmo" in Hepatology clinic. European and rest of the world colleagues please indulge. #fibroscan http://t.co/2zzLNkCVgk